New drug aripiprazole of class 3.1 of Enhua pharmaceutical is undergoing three in one review, which is expected to be approved within this year

Aripiprazole is a new type of atypical antipsychotic drug, which was listed in China in 2004 Due to the remarkable curative effect on the positive and negative symptoms of schizophrenia, the products grow rapidly after being put on the market The compound growth rate of the drug was 41.16% in 2006-2010, and the domestic market scale was about 400 million by 2010 According to CFDA, at present, Zhejiang Otsuka, Chengdu Kanghong and Shanghai Sino Western pharmaceutical have obtained approval documents for pharmaceutical production At the same time, in addition to the Enhua pharmaceutical industry, there are also enterprises such as Huahai Pharmaceutical (600521 SH), Qilu pharmaceutical and hausen pharmaceutical in R & D Enhua Pharmaceutical Co., Ltd is the leader of central nervous system medicine in China The main products of the company, midazolam and risperidone, are affected by the administrative price reduction, and the product growth slows down The market hopes that the company's reserve varieties will be approved and listed, creating new performance growth points.